European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Palbociclib Viatris, palbociclib, Date of authorisation: 19/06/2026, Status: Authorised

Submitted by Anonymous (not verified) on 23 June 2026 - 12:20

Human medicines European public assessment report (EPAR): Palbociclib Viatris, palbociclib, Date of authorisation: 19/06/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Agamree, vamorolone, Date of authorisation: 14/12/2023, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 23 June 2026 - 11:55

Human medicines European public assessment report (EPAR): Agamree, vamorolone, Date of authorisation: 14/12/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Adstiladrin, nadofaragene firadenovec, Date of authorisation: 28/05/2026, Status: Authorised

Submitted by Anonymous (not verified) on 23 June 2026 - 10:32

Human medicines European public assessment report (EPAR): Adstiladrin, nadofaragene firadenovec, Date of authorisation: 28/05/2026, Status: Authorised

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 June 2026, 12:30 (CEST) to 17 June 2026, 17:30 (CEST)

Submitted by Anonymous (not verified) on 23 June 2026 - 9:14

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 June 2026, 12:30 (CEST) to 17 June 2026, 17:30 (CEST)

Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0352/2022

Submitted by Anonymous (not verified) on 23 June 2026 - 8:35

Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0352/2022

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness